AI-based wearable ECG monitoring predicted 6–12-month changes in NT-proBNP with a directional accuracy of 82% in patients with persistent atrial fibrillation and heart failure.
Observational (n=50)
No
Does an AI model using wearable ECG-derived features predict longitudinal changes in NT-proBNP in patients with persistent atrial fibrillation?
Wearable ECG-derived digital biomarkers combined with AI can feasibly predict longitudinal trends in NT-proBNP in patients with persistent atrial fibrillation, offering a potential non-invasive approach for heart failure monitoring.
Effect estimate: directional accuracy 0.82
Background Persistent atrial fibrillation (AF) frequently coexists with heart failure (HF), yet HF monitoring remains limited by the need for repeated blood-based biomarkers such as N-terminal pro-brain natriuretic peptide (NT-proBNP). Advances in wearable electrocardiography (ECG) and artificial intelligence (AI) now allow continuous extraction of digital physiologic signatures that may reflect hemodynamic stress. Objective To evaluate the feasibility of predicting HF progression using wearable ECG–derived features in patients with persistent AF. Methods Fifty patients with persistent AF underwent 3–7 days of single-lead ECG monitoring. Heart rate variability (HRV) and RR-interval features from 30 min windows were combined with baseline clinical metrics. A context-aware deep learning model using long short-term memory (LSTM) and attention mechanisms was trained to predict 6–12-month NT-proBNP changes. Model performance was assessed using root mean squared error (RMSE), mean absolute error (MAE), and the accuracy of directional NT-proBNP change. Results The best performance was achieved when clinical metrics, RR features, and long-term HRV summaries were combined (RMSE 1,667.04; MAE 950.52). Directional classification of NT-proBNP trajectories achieved an accuracy of 0.82. ECG-only models performed comparably to multimodal models. Conclusion Wearable ECG–based AI modeling is feasible for predicting trends in HF biomarkers in persistent AF. These results provide early evidence that ECG-derived digital biomarkers may offer a scalable, non-invasive approach for longitudinal HF monitoring.
Song et al. (Thu,) conducted a observational in persistent atrial fibrillation with heart failure with preserved ejection fraction (n=50). wearable single-lead ECG monitoring with AI-based prediction model was evaluated on prediction of 6–12-month change in NT-proBNP levels as a marker of heart failure progression (directional accuracy 0.82). AI-based wearable ECG monitoring predicted 6–12-month changes in NT-proBNP with a directional accuracy of 82% in patients with persistent atrial fibrillation and heart failure.